Cancer Risk in People Without Diabetes

Most studies of these drugs and cancer are done in people with diabetes, where the comparison drug is itself a marker of how sick someone is. This one was done in obese adults without diabetes, and found 41% lower incidence of obesity-associated cancers.^[1] It also has a median follow-up of two years, which is the problem.

What was found

After propensity score matching, GLP-1 users had a significantly lower incidence of obesity-associated cancers, with a hazard ratio of 0.59 (95% CI 0.53 to 0.67). Participants had a mean age of 47.2. An inverse probability of treatment weighting analysis confirmed the finding, and it held across subgroups — with one exception discussed below.^[1]

The population is the genuine contribution. We have written about a study reporting 91% lower breast cancer mortality that evaporated against a fair comparator, because insulin users are sicker than GLP-1 users by definition. Studying people without diabetes removes that specific problem.

Two years is not long enough to answer this

A cancer diagnosed within two years of starting a drug was, in most cases, already there when the drug started.

Solid tumors develop over years to decades. A median follow-up of two years, with an interquartile range of one to two, captures diagnoses rather than causation. The authors describe the result as a short-term incidence finding and call for prospective trials to confirm causality.^[1]

This is the same structural limitation we found in the randomized evidence: a systematic review in the Annals of Internal Medicine concluded these drugs may have little or no effect on obesity-related cancers, while noting the included trials were not designed to evaluate cancer outcomes and had short follow-up. That is in the randomized answer.

The subgroup that did not follow the pattern

The association held in every subgroup examined except black race.^[1] That finding deserves careful handling, and the careful reading is not a biological one.

We covered the same shape in who responds in the real world, where a real-world cohort found weight-loss outcomes differing by race while 64 randomized trials found none. The explanation there applies here: trials equalize access, continuity and follow-up, and ordinary care does not. A benefit that requires sustained treatment will appear smaller in any group whose treatment is more often interrupted — and a benefit measured by diagnosis also depends on who receives screening.

Reading a subgroup difference in an observational cancer study as a difference in how bodies respond, rather than in how care is delivered, would be unsupported by the randomized evidence and would mislocate the problem.

Where this leaves the question

• The direction is consistent across cohorts, drug classes and now a nondiabetic population. Consistency is worth something.
• The magnitude is not. A 41% reduction is large enough to trigger the rule we set out in when a hazard ratio is too good: in observational data, big effects usually describe who was prescribed the drug.
• The mechanism is plausible. Obesity is an established driver of the thirteen cancer types usually classed as obesity-associated, and these drugs reduce obesity.
• The follow-up cannot support the claim. Two years is the wrong instrument for this question, whatever it reads.

Nothing here is a reason to take or avoid one of these drugs on cancer grounds, and no GLP-1 is indicated for cancer prevention anywhere.